ERAS UPCOMING DEADLINE: SueWallSt Alerts Erasca, Inc. Stockholders of Securities Class Action

SueWallSt is alerting stockholders of Erasca, Inc. (NASDAQ: ERAS) about an upcoming deadline in a securities class action lawsuit. The lawsuit alleges that Erasca's SEC filings failed to adequately warn investors that the competitive comparisons for its drug candidate ERAS-0015 were scientifically unsupported and legally vulnerable, contributing to a 53.9% stock price collapse. Investors who purchased ERAS stock between January 14, 2025, and April 26, 2026, may qualify to recover losses. The lead plaintiff deadline is August 10, 2026. The complaint contends that Erasca's 2024 and 2025 Annual Reports on Form 10-K presented detailed preclinical data comparing ERAS-0015 to Revolution Medicines' (RevMed) RMC-6236, claiming ERAS-0015 was a "potential best-in-class" drug candidate with strong intellectual property. However, the lawsuit alleges that these disclosures omitted critical information: the comparisons were cross-study analyses, not head-to-head trials; RevMed had grounds to allege patent infringement and trade secret misappropriation, contradicting Erasca's claims of no patentability roadblocks; and RevMed characterized Erasca's statements as deceptive. Furthermore, the initial Phase 1 trial data included a Grade 5 patient death, which was not disclosed alongside earlier safety claims. The company raised approximately $258.8 million through a stock offering in January 2026 while these risks were allegedly undisclosed. The lawsuit argues that Erasca's risk factor language was generic and that boilerplate warnings may not shield the company from liability because specific, known problems were not disclosed.